Kim Kang-Min, Park Chul-Kee, Chung Hyun-Tai, Paek Sun Ha, Jung Hee-Won, Kim Dong Gyu
Department of Neurosurgery, Seoul National University, College of Medicine, Seoul, Korea.
J Korean Neurosurg Soc. 2007 Oct;42(4):286-92. doi: 10.3340/jkns.2007.42.4.286. Epub 2007 Oct 20.
Gamma Knife Stereotactic Radiosurgery (GK SRS) has become an important treatment modality for vestibular schwannomas. We evaluated the tumor control rate, patterns of tumor volume change and preservation of hearing following low-dose radiation for vestibular schwannomas in a homogeneous cohort group in which the mean marginal dose was 12 Gy.
A total of 59 patients were enrolled in this study. All enrolled patients were followed-up for at least 5 years and the radiation dose was 11-13 Gy. Regular MRI, audiometry and clinical evaluations were done and tumor volumes were obtained from MRI using the OSIRIS program.
The tumor control rate was 97%. We were able to classify the patterns of change in tumor volume into three categories. Transient increases in tumor volume were detected in 29% of the patients and the maximum transient increase in tumor volume was identified at 6 to 30 months after GK SRS. The transient increases in tumor volume ranged from 121% to 188%. Hearing was preserved in 4 of the 12 patients who had serviceable hearing prior to treatment. There were no other complications associated with GK SRS.
Low-dose GK SRS was an effective and safe mode of treatment for vestibular schwannomas in comparison to the previously used high-dose GK SRS. Transient increases in tumor volume can be identified during the follow-up period after low-dose GK SRS for vestibular schwannomas. Physicians should be aware that these increases are not always indicative of treatment failure and that close observation is required following treatments. Unfortunately, a satisfactory hearing preservation rate was not achieved by reducing the radiation dose. It is thought that hearing preservation is a more sophisticated problem and further research is required.
伽玛刀立体定向放射外科治疗(GK SRS)已成为前庭神经鞘瘤的一种重要治疗方式。我们评估了平均边缘剂量为12 Gy的低剂量放射治疗前庭神经鞘瘤后的肿瘤控制率、肿瘤体积变化模式及听力保留情况。
本研究共纳入59例患者。所有纳入患者均随访至少5年,放射剂量为11 - 13 Gy。进行了常规MRI、听力测定及临床评估,并使用OSIRIS程序从MRI获取肿瘤体积。
肿瘤控制率为97%。我们能够将肿瘤体积变化模式分为三类。29%的患者检测到肿瘤体积短暂增加,GK SRS后6至30个月出现肿瘤体积最大短暂增加。肿瘤体积短暂增加范围为121%至188%。治疗前听力尚可的12例患者中有4例听力得以保留。未发现与GK SRS相关的其他并发症。
与先前使用的高剂量GK SRS相比,低剂量GK SRS是治疗前庭神经鞘瘤的一种有效且安全的方式。低剂量GK SRS治疗前庭神经鞘瘤后的随访期间可发现肿瘤体积短暂增加。医生应意识到这些增加并不总是表明治疗失败,治疗后需要密切观察。遗憾的是,降低放射剂量并未实现令人满意的听力保留率。认为听力保留是一个更复杂的问题,需要进一步研究。